Latrophilin-2 Deletion in Cardiomyocyte Disrupts Cell Junction, Leading to D-CMP
- 8 November 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 135 (11) , 1098-1115
Abstract
BACKGROUND: Latrophilin-2 (Lphn2), an adhesive GPCR (G protein-coupled receptor), was found to be a specific marker of cardiac progenitors during the differentiation of pluripotent stem cells into cardiomyocytes or during embryonic heart development in our previous studies. Its role in adult heart physiology, however, remains unclear. METHODS: The embryonic lethality resulting from Lphn2 deletion necessitates the establishment of cardiomyocyte-specific, tamoxifen-inducible Lphn2 knockout mice, which was achieved by crossing Lphn2 flox/flox mice with mice having MerCreMer (tamoxifen-inducible Cre [Cyclization recombinase] recombinase) under the α-myosin heavy chain promoter. RESULTS: Tamoxifen treatment for several days completely suppressed Lphn2 expression, specifically in the myocardium, and induced the dilated cardiomyopathy (D-CMP) phenotype with serious arrhythmia and sudden death in a short period of time. Transmission electron microscopy showed mitochondrial abnormalities, blurred Z-discs, and dehiscent myofibrils. The D-CMP phenotype, or heart failure, worsened during myocardial infarction. In a mechanistic study of D-CMP, Lphn2 knockout suppressed PGC-1α (Peroxisome proliferator-activated receptor gamma coactivator 1-alpha) and mitochondrial dysfunction, leading to the accumulation of reactive oxygen species and the global suppression of junctional molecules, such as N-cadherin (adherens junction), DSC-2 (desmocollin-2; desmosome), and connexin-43 (gap junction), leading to the dehiscence of cardiac myofibers and serious arrhythmia. In an experimental therapeutic trial, activators of p38-MAPK (p38 mitogen-activated protein kinases), which is a downstream signaling molecule of Lphn2, remarkably rescued the D-CMP phenotype of Lphn2 knockout in the heart by restoring PGC-1α and mitochondrial function and recovering global junctional proteins. CONCLUSIONS: Lphn2 is a critical regulator of heart integrity by controlling mitochondrial functions and cell-to-cell junctions in cardiomyocytes. Its deficiency leads to D-CMP, which can be rescued by activators of the p38-MAPK pathway.Keywords
This publication has 42 references indexed in Scilit:
- Adhesion GPCR Latrophilin-2 Specifies Cardiac Lineage Commitment through CDK5, Src, and P38MAPKStem Cell Reports, 2021
- Lysophosphatidic Acid Receptor 4 Is Transiently Expressed during Cardiac Differentiation and Critical for Repair of the Damaged HeartMolecular Therapy, 2021
- Impact of Oxidative Stress on the Heart and VasculatureJACC, 2017
- Secondary Sphere Formation Enhances the Functionality of Cardiac Progenitor CellsMolecular Therapy, 2012
- Dilated cardiomyopathyThe Lancet, 2010
- Latrophilin‐2 is a novel component of the epithelial‐mesenchymal transition within the atrioventricular canal of the embryonic chicken heartDevelopmental Dynamics, 2006
- Complementary action of the PGC-1 coactivators in mitochondrial biogenesis and brown fat differentiationCell Metabolism, 2006
- Mitochondria, Oxidants, and AgingCell, 2005
- Chronic regulation of the expression of gap junction proteins connexin40, connexin43, and connexin45 in neonatal rat cardiomyocytesEuropean Journal of Pharmacology, 2004
- Cytokine Stimulation of Energy Expenditure through p38 MAP Kinase Activation of PPARγ Coactivator-1Molecular Cell, 2001